ECSP22021881A - Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso - Google Patents

Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso

Info

Publication number
ECSP22021881A
ECSP22021881A ECSENADI202221881A ECDI202221881A ECSP22021881A EC SP22021881 A ECSP22021881 A EC SP22021881A EC SENADI202221881 A ECSENADI202221881 A EC SENADI202221881A EC DI202221881 A ECDI202221881 A EC DI202221881A EC SP22021881 A ECSP22021881 A EC SP22021881A
Authority
EC
Ecuador
Prior art keywords
prolgolimab
antibody
pharmaceutical composition
aqueous pharmaceutical
aqueous compositions
Prior art date
Application number
ECSENADI202221881A
Other languages
English (en)
Inventor
Ekaterina Aleksandrovna Lomkova
Aleksandr Olegovich Iakovlev
Mariia Stanislavovna Shustova
Alina Aleksandrovna Tsukur
Viktoriya Olegovna Shitikova
Olesya Nikolaevna Kozlova
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2019126511A external-priority patent/RU2806320C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of ECSP22021881A publication Critical patent/ECSP22021881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a las nuevas composiciones acuosas de los anticuerpos anti-PD-1, y en particular a las nuevas composiciones acuosas del anticuerpo anti-PD-1 prolgolimab, que pueden usarse como un agente medicinal para el tratamiento de neoplasias malignas.
ECSENADI202221881A 2019-08-22 2022-03-22 Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso ECSP22021881A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019126511A RU2806320C2 (ru) 2019-08-22 Водная фармацевтическая композиция антитела к pd-1 пролголимаба и ее применение

Publications (1)

Publication Number Publication Date
ECSP22021881A true ECSP22021881A (es) 2022-04-29

Family

ID=71558267

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202221881A ECSP22021881A (es) 2019-08-22 2022-03-22 Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso

Country Status (21)

Country Link
US (1) US20250262153A1 (es)
EP (1) EP4019047A4 (es)
JP (1) JP7621340B2 (es)
KR (1) KR20220147061A (es)
CN (1) CN111420049A (es)
AR (1) AR119805A1 (es)
AU (1) AU2020333023A1 (es)
BR (1) BR112022003378A2 (es)
CA (1) CA3148978A1 (es)
CO (1) CO2022001829A2 (es)
EC (1) ECSP22021881A (es)
JO (1) JOP20220045A1 (es)
MA (2) MA61742A1 (es)
MX (1) MX2022002185A (es)
PE (1) PE20220932A1 (es)
PH (1) PH12022550432A1 (es)
PY (1) PY2047856A (es)
TW (1) TWI844666B (es)
UY (1) UY38851A (es)
WO (1) WO2021034228A1 (es)
ZA (1) ZA202202243B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111965372B (zh) * 2020-09-03 2024-05-31 北京安图生物工程有限公司 免疫球蛋白e检测试剂盒及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325974B2 (en) * 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
EP3848393A1 (en) * 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
CA3118690A1 (en) * 2018-11-05 2020-05-14 Aveo Pharmaceuticals, Inc. Use of tivozanib to treat subjects with refractory cancer

Also Published As

Publication number Publication date
RU2019126511A (ru) 2021-02-24
AU2020333023A1 (en) 2022-11-03
PH12022550432A1 (en) 2024-01-29
MA56263A1 (fr) 2022-11-30
AR119805A1 (es) 2022-01-12
JP2022544850A (ja) 2022-10-21
BR112022003378A2 (pt) 2022-05-17
TWI844666B (zh) 2024-06-11
EP4019047A1 (en) 2022-06-29
CN111420049A (zh) 2020-07-17
PE20220932A1 (es) 2022-05-31
ZA202202243B (en) 2024-09-25
JOP20220045A1 (ar) 2023-01-30
WO2021034228A1 (ru) 2021-02-25
MA61742A1 (fr) 2023-11-30
PY2047856A (es) 2021-03-19
MX2022002185A (es) 2022-04-20
CA3148978A1 (en) 2021-02-25
RU2019126511A3 (es) 2021-04-30
CO2022001829A2 (es) 2022-03-29
JP7621340B2 (ja) 2025-01-24
KR20220147061A (ko) 2022-11-02
TW202114637A (zh) 2021-04-16
US20250262153A1 (en) 2025-08-21
EP4019047A4 (en) 2023-06-07
UY38851A (es) 2021-02-26

Similar Documents

Publication Publication Date Title
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2017013270A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
PE20220220A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112022002653A2 (pt) Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2025001913A1 (es) Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso.
MX2018005379A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2021002574A1 (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
CL2021003228A1 (es) Compuestos tricíclicos y su uso
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2017013571A (es) Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap).